+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Oral Antibiotics Market, by Class, Application, Drug Origin, Spectrum of Activity and Drug Type: Global Opportunity Analysis and Industry Forecast, 2020-2027

  • PDF Icon

    Report

  • 329 Pages
  • June 2020
  • Region: Global
  • Allied Market Research
  • ID: 5134111
UP TO OFF until Mar 31st 2023
The global oral antibiotics market generated $18,365.80 million in 2018, and is projected to reach $23,306.10 million by 2027, growing at a CAGR of 2.7% from 2019 to 2027.


Antibiotic is an antimicrobial substance or a compound that fights against bacterial infections and sometimes with protozoan infections, but not viral infections. These are medications that either stop bacteria from growing or kill bacteria directly, referred as bacteriostatic and bactericidal antibiotics, respectively. There are several types of antibiotics easily available at drug stores and in hospitals with a prescription or without a prescription in most of countries. Antibiotics are mostly used during transplants, dialysis, suppressed immune system, and joint replacement.

There is an increase in demand for antibiotics, owing to an increased consumption in low- and middle-income countries (LMICs) and a rise in the prevalence of infectious diseases. In addition, development of novel approaches for new antibiotics to treat bacterial infections and large number of clinical trials further drive market growth. However, development of antibiotic resistance, driven by misuse of antibiotics and time taken for regulatory approvals are projected to impede market growth. On the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.

The global oral antibiotics market is segmented on the basis of class, application drug origin, spectrum of activity, application, and region. On the basis of class, the market is classified into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. Beta lactam & beta lactamase inhibitors is further segmented into Penicillin, Cephalosporin, and others. By application, the market is divided into community- respiratory tract infections (CARTIS), urinary acquired tract infections (UTIS), dental, and others. Depending on drug origin, it is categorized into natural, semisynthetic, and synthetic.
According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. By drug type, it is divided into branded and generics. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Depending on class, the market is categorized into Beta lactam & beta lactamase inhibitors, Quinolones, Macrolide, and Others. The beta lactam & beta lactamase inhibitors segment was the highest contributor to the market in 2018. The segment is a major revenue contributor, owing to its broad-spectrum of activity A broad-spectrum antibiotic fights both Gram-negative and Gram-positive bacteria as well as effective on the multiple groups of bacterial infections.

On the basis of application, the oral antibiotics market is classified into community-acquired respiratory tract infections (CARTIs), urinary tract infections (UTIs), dental, and others. The CARTIs segment is further segmented into upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI). The dental segment is further divided into combination and monotherapies.

On the basis of drug origin, the oral antibiotics market is classified into natural, semisynthetic, and synthetic. The synthetic segment generated highest revenue in 2018, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the fact that semisynthetic oral antibiotics have improved coverage and effectiveness against a wide range of organisms.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the global oral antibiotics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2020 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global oral antibiotics market growth.

KEY MARKET SEGMENTS

By Class
  • Beta Lactam and Beta Lactamase Inhibitors
  • Penicillin
  • Broad Spectrum Penicillin
  • Mid/Narrow Spectrum Penicillin
  • Cephalosporin
  • Others
  • Quinolone
  • Macrolide
  • Others

By Application
  • Community-respiratory tract infections (CARTIS)
  • Upper Respiratory Tract Infections (URTI)
  • Lower Respiratory Tract Infections (LRTI)
  • Urinary acquired tract infections (UTIS)
  • Dental
  • Combination
  • Monotherapies
  • Others

By Drug Origin
  • Natural
  • Semisynthetic
  • Synthetic

By Spectrum of Activity
  • Broad-spectrum Antibiotic
  • Narrow-spectrum Antibiotic

By Drug Type
  • Branded
  • Generic

By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Russia
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Pakistan
  • Vietnam
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Turkey
  • Rest of LAMEA
List of key players profiled in the report
  • Abbott Laboratories
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled in the Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.1.1. CXO Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Market Share Analysis, 2018
3.4. Porter’sFive Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increase in Consumption in Low-And Middle-Income Countries (Lmics)
3.5.1.2. Rise in Prevalence of Infectious Diseases
3.5.1.3. Development of Novel Approaches
3.5.2. Restraints
3.5.2.1. Development of Antibiotic Resistance
3.5.2.2. Time Consuming Approvals
3.5.3. Opportunities
3.5.3.1. Discovery of Advanced Therapies to Treat Antibiotic-Resistance.
3.6. Impact Analysis of Covid-19 on Oral Antibiotics Market
Chapter 4: Oral Antibiotics Market, by Class
4.1. Overview
4.1.1. Market Size and Forecast, by Class
4.2. Beta Lactam and Beta Lactamase Inhibitors
4.2.1. Key Market Trends and Growth Opportunities
4.2.2. Market Size and Forecast, by Type
4.2.2.1. Penicillin
4.2.2.1.1. Market Size and Forecast, by Type
4.2.2.1.1.1. Broad-Spectrum Penicillin
4.2.2.1.1.2. Mid/Narrow-Spectrum Penicillin
4.2.2.2. Cephalosporin
4.2.2.2.1. Market Size and Forecast
4.2.2.2.2. Market Size and Forecast, by Molecule
4.2.2.3. Others
4.2.2.3.1. Market Size and Forecast
4.2.3. Market Size and Forecast, by Region
4.2.4. Market Analysis, by Country
4.3. Quinolones
4.3.1. Key Market Trends and Growth Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Macrolides
4.4.1. Key Market Trends and Growth Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Others
4.5.1. Key Market Trends and Growth Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
Chapter 5: Oral Antibiotics Market, by Application
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Community-Acquired Respiratory Tract Infections (Cartis)
5.2.1. Market Size and Forecast, by Type
5.2.1.1. Upper Respiratory Tract Infections (Urti)
5.2.1.1.1. Market Size and Forecast
5.2.1.1.2. Market Size and Forecast, by Molecule
5.2.1.2. Lower Respiratory Tract Infections (Lrtis)
5.2.1.2.1. Market Size and Forecast
5.2.1.2.2. Market Size and Forecast, by Molecule
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Analysis, by Country
5.3. Urinary Tract Infections (Utis)
5.3.1. Market Size and Forecast, by Molecule
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Analysis, by Country
5.4. Dental
5.4.1. Market Size and Forecast, by Type
5.4.1.1. Combination
5.4.1.1.1. Market Size and Forecast
5.4.1.1.2. Market Size and Forecast, by Molecule
5.4.1.2. Monotherapies
5.4.1.2.1. Market Size and Forecast
5.4.1.2.2. Market Size and Forecast, by Molecule
5.4.2. Market Size and Forecast, by Region
5.4.3. Market Analysis, by Country
5.5. Others
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Analysis, by Country
Chapter 6: Oral Antibiotics Market, by Drug Origin
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Natural
6.2.1. Market Size and Forecast, by Region
6.2.2. Market Analysis, by Country
6.3. Semisynthetic
6.3.1. Market Size and Forecast, by Region
6.3.2. Market Analysis, by Country
6.4. Synthetic
6.4.1. Market Size and Forecast, by Region
6.4.2. Market Analysis, by Country
Chapter 7: Oral Antibiotics Market, by Spectrum of Activity
7.1. Overview
7.1.1. Market Size and Forecast
7.2. Broad-Spectrum Antibiotic
7.2.1. Market Size and Forecast, by Region
7.2.2. Market Analysis, by Country
7.3. Mid/Narrow-Spectrum Antibiotic
7.3.1. Market Size and Forecast, by Region
7.3.2. Market Analysis, by Country
Chapter 8: Oral Antibiotics Market, by Drug Type
8.1. Overview
8.1.1. Market Size and Forecast
8.2. Branded
8.2.1. Market Size and Forecast, by Region
8.2.2. Market Analysis, by Country
8.3. Generics
8.3.1. Market Size and Forecast, by Region
8.3.2. Market Analysis, by Country
Chapter 9: Oral Antibiotics Market, by Region
9.1. Overview
9.1.1. Market Size and Forecast
9.2. North America
9.2.1. Key Market Trends and Opportunities
9.2.2. North America Antibiotics Market, by Country
9.2.2.1. U. S. Oral Antibiotics Market, by Class
9.2.2.2. U. S. Oral Antibiotics Market, by Application
9.2.2.3. U. S. Oral Antibiotics Market, by Drug Origin
9.2.2.4. U. S. Oral Antibiotics Market, by Spectrum of Activity
9.2.2.5. U. S. Oral Antibiotics Market, by Drug Type
9.2.2.6. Canada Oral Antibiotics Market, by Class
9.2.2.7. Canada Oral Antibiotics Market, by Application
9.2.2.8. Canada Oral Antibiotics Market, by Drug Origin
9.2.2.9. Canada Oral Antibiotics Market, by Spectrum of Activity
9.2.2.10. Canada Oral Antibiotics Market, by Drug Type
9.2.2.11. Mexico Oral Antibiotics Market, by Class162
9.2.2.12. Mexico Oral Antibiotics Market, by Application
9.2.2.13. Mexico Oral Antibiotics Market, by Drug Origin
9.2.2.14. Mexico Oral Antibiotics Market, by Spectrum of Activity
9.2.2.15. Mexico Oral Antibiotics Market, by Drug Type
9.2.3. North America Oral Antibiotics Market, by Class
9.2.4. North America Oral Antibiotics Market, by Application
9.2.5. North America Oral Antibiotics Market, by Drug Origin
9.2.6. North America Oral Antibiotics Market, by Spectrum of Activity
9.2.7. North America Antibiotics Market, by Drug Type
9.3. Europe
9.3.1. Key Market Trends and Opportunities
9.3.2. Europe Oral Antibiotics Market, by Country
9.3.2.1. Germany Oral Antibiotics Market, by Class
9.3.2.2. Germany Oral Antibiotics Market, by Application
9.3.2.3. Germany Oral Antibiotics Market, by Drug Origin
9.3.2.4. Germany Oral Antibiotics Market, by Spectrum of Activity
9.3.2.5. Germany Oral Antibiotics Market, by Drug Type
9.3.2.6. France Oral Antibiotics Market, by Class
9.3.2.7. France Oral Antibiotics Market, by Application
9.3.2.8. France Oral Antibiotics Market, by Drug Origin
9.3.2.9. France Oral Antibiotics Market, by Spectrum of Activity
9.3.2.10. France Oral Antibiotics Market, by Drug Type
9.3.2.11. Spain Oral Antibiotics Market, by Class181
9.3.2.12. Spain Oral Antibiotics Market, by Application
9.3.2.13. Spain Oral Antibiotics Market, by Drug Origin
9.3.2.14. Spain Oral Antibiotics Market, by Spectrum of Activity
9.3.2.15. Spain Oral Antibiotics Market, by Drug Type
9.3.2.16. Italy Oral Antibiotics Market, by Class185
9.3.2.17. Italy Oral Antibiotics Market, by Application
9.3.2.18. Italy Oral Antibiotics Market, by Drug Origin
9.3.2.19. Italy Oral Antibiotics Market, by Spectrum of Activity
9.3.2.20. Italy Oral Antibiotics Market, by Drug Type
9.3.2.21. UK Oral Antibiotics Market, by Class
9.3.2.22. UK Oral Antibiotics Market, by Application
9.3.2.23. UK Oral Antibiotics Market, by Drug Origin
9.3.2.24. UK Oral Antibiotics Market, by Spectrum of Activity
9.3.2.25. UK Oral Antibiotics Market, by Drug Type
9.3.2.26. Russia Oral Antibiotics Market, by Class
9.3.2.27. Russia Oral Antibiotics Market, by Application
9.3.2.28. Russia Oral Antibiotics Market, by Drug Origin
9.3.2.29. Russia Oral Antibiotics Market, by Spectrum of Activity
9.3.2.30. Russia Oral Antibiotics Market, by Drug Type
9.3.2.31. Rest of Europe Oral Antibiotics Market, by Class
9.3.2.32. Rest of Europe Oral Antibiotics Market, by Application
9.3.2.33. Rest of Europe Oral Antibiotics Market, by Drug Origin
9.3.2.34. Rest of Europe Oral Antibiotics Market, by Spectrum of Activity
9.3.2.35. Rest of Europe Oral Antibiotics Market, by Drug Type
9.3.3. Europe Oral Antibiotics Market, by Class
9.3.4. Europe Oral Antibiotics Market, by Application
9.3.5. Europe Oral Antibiotics Market, by Drug Origin
9.3.6. Europe Oral Antibiotics Market, by Spectrum of Activity
9.3.7. Europe Oral Antibiotics Market, by Drug Type
9.4. Asia-Pacific
9.4.1. Key Market Trends and Opportunities
9.4.2. Asia-Pacific Oral Antibiotics Market, by Country
9.4.2.1. Japan Oral Antibiotics Market, by Class
9.4.2.2. Japan Oral Antibiotics Market, by Application
9.4.2.3. Japan Oral Antibiotics Market, by Drug Origin
9.4.2.4. Japan Oral Antibiotics Market, by Spectrum of Activity
9.4.2.5. Japan Oral Antibiotics Market, by Drug Type
9.4.2.6. India Oral Antibiotics Market, by Class
9.4.2.7. India Oral Antibiotics Market, by Application
9.4.2.8. India Oral Antibiotics Market, by Drug Origin
9.4.2.9. India Oral Antibiotics Market, by Spectrum of Activity
9.4.2.10. India Oral Antibiotics Market, by Drug Type
9.4.2.11. China Oral Antibiotics Market, by Class
9.4.2.12. China Oral Antibiotics Market, by Application
9.4.2.13. China Oral Antibiotics Market, by Drug Origin
9.4.2.14. China Oral Antibiotics Market, by Spectrum of Activity
9.4.2.15. China Oral Antibiotics Market, by Drug Type
9.4.2.16. Pakistan Oral Antibiotics Market, by Class
9.4.2.17. Pakistan Oral Antibiotics Market, by Application
9.4.2.18. Pakistan Oral Antibiotics Market, by Drug Origin
9.4.2.19. Pakistan Oral Antibiotics Market, by Spectrum of Activity
9.4.2.20. Pakistan Oral Antibiotics Market, by Drug Type
9.4.2.21. Vietnam Oral Antibiotics Market, by Class
9.4.2.22. Vietnam Oral Antibiotics Market, by Application
9.4.2.23. Vietnam Oral Antibiotics Market, by Drug Origin
9.4.2.24. Vietnam Oral Antibiotics Market, by Spectrum of Activity
9.4.2.25. Vietnam Oral Antibiotics Market, by Drug Type
9.4.2.26. Rest of Asia-Pacific Oral Antibiotics Market, by Class
9.4.2.27. Rest of Asia-Pacific Oral Antibiotics Market, by Application
9.4.2.28. Rest of Asia-Pacific Oral Antibiotics Market, by Drug Origin
9.4.2.29. Rest of Asia-Pacific Oral Antibiotics Market, by Spectrum of Activity
9.4.2.30. Rest of Asia-Pacific Oral Antibiotics Market, by Drug Type
9.4.3. Asia-Pacific Oral Antibiotics Market, by Class
9.4.4. Asia-Pacific Oral Antibiotics Market, by Application
9.4.5. Asia-Pacific Oral Antibiotics Market, by Drug Origin
9.4.6. Asia-Pacific Oral Antibiotics Market, by Spectrum of Activity
9.4.7. Asia-Pacific Oral Antibiotics Market, by Drug Type
9.5. LAMEA
9.5.1. Key Market Trends and Opportunities
9.5.2. LAMEA Antibiotics Market, by Country
9.5.2.1. Brazil Oral Antibiotics Market, by Class
9.5.2.2. Brazil Oral Antibiotics Market, by Application
9.5.2.3. Brazil Oral Antibiotics Market, by Drug Origin
9.5.2.4. Brazil Oral Antibiotics Market, by Spectrum of Activity
9.5.2.5. Brazil Oral Antibiotics Market, by Drug Type
9.5.2.6. Saudi Arabia Oral Antibiotics Market, by Class
9.5.2.7. Saudi Arabia Oral Antibiotics Market, by Application
9.5.2.8. Saudi Arabia Oral Antibiotics Market, by Drug Origin
9.5.2.9. Saudi Arabia Oral Antibiotics Market, by Spectrum of Activity
9.5.2.10. Saudi Arabia Oral Antibiotics Market, by Application
9.5.2.11. South Africa Oral Antibiotics Market, by Class
9.5.2.12. South Africa Oral Antibiotics Market, by Application
9.5.2.13. South Africa Oral Antibiotics Market, by Drug Origin
9.5.2.14. South Africa Oral Antibiotics Market, by Spectrum of Activity
9.5.2.15. South Africa Oral Antibiotics Market, by Drug Type
9.5.2.16. Turkey Oral Antibiotics Market, by Class
9.5.2.17. Turkey Oral Antibiotics Market, by Application
9.5.2.18. Turkey Oral Antibiotics Market, by Drug Origin
9.5.2.19. Turkey Oral Antibiotics Market, by Spectrum of Activity
9.5.2.20. Turkey Oral Antibiotics Market, by Drug Type
9.5.2.21. Rest of LAMEA Oral Antibiotics Market, by Class
9.5.2.22. Rest of LAMEA Oral Antibiotics Market, by Application
9.5.2.23. Rest of LAMEA Oral Antibiotics Market, by Drug Origin
9.5.2.24. Rest of LAMEA Oral Antibiotics Market, by Spectrum of Activity
9.5.2.25. Rest of LAMEA Oral Antibiotics Market, by Drug Type
9.5.3. LAMEA Antibiotics Market, by Class
9.5.4. LAMEA Antibiotics Market, by Application
9.5.5. LAMEA Antibiotics Market, by Drug Origin
9.5.6. LAMEA Antibiotics Market, by Spectrum of Activity
9.5.7. LAMEA Antibiotics Market, by Drug Type
Chapter 10: Company Profiles
10.1. Abbott Laboratories
10.1.1. Company Overview
10.1.2. Company Snapshot
10.1.3. Operating Business Segments
10.1.4. Product Portfolio
10.1.5. Business Performance
10.2. Allergan plc
10.2.1. Company Overview
10.2.2. Company Snapshot
10.2.3. Operating Business Segments
10.2.4. Product Portfolio
10.2.5. Business Performance
10.2.6. Key Strategic Moves and Developments
10.3. F. Hoffmann-La Roche Ltd.
10.3.1. Company Overview
10.3.2. Company Snapshot
10.3.3. Operating Business Segments
10.3.4. Product Portfolio
10.3.5. Business Performance
10.3.6. Key Strategic Moves and Developments
10.4. GlaxoSmithKline plc
10.4.1. Company Overview
10.4.2. Company Snapshot
10.4.3. Operating Business Segments
10.4.4. Product Portfolio
10.4.5. Business Performance
10.4.6. Key Strategic Moves and Developments
10.5. Merck & Co. Inc.
10.5.1. Company Overview
10.5.2. Company Snapshot
10.5.3. Operating Business Segments
10.5.4. Product Portfolio
10.5.5. Business Performance
10.5.6. Key Strategic Moves and Developments
10.6. Mylan N. V.
10.6.1. Company Overview
10.6.2. Company Snapshot
10.6.3. Operating Business Segments
10.6.4. Product Portfolio
10.6.5. Business Performance
10.6.6. Key Strategic Moves and Developments
10.7. Novartis International AG (Pear Therapeutics, Inc.)
10.7.1. Company Overview
10.7.2. Company Snapshot
10.7.3. Operating Business Segments
10.7.4. Product Portfolio
10.7.5. Business Performance
10.7.6. Key Strategic Moves and Developments
10.8. Pfizer Inc.
10.8.1. Company Overview
10.8.2. Company Snapshot
10.8.3. Operating Business Segments
10.8.4. Operating Product
10.8.5. Business Performance
10.8.6. Key Strategic Moves and Developments
10.9. Sanofi
10.9.1. Company Overview
10.9.2. Company Snapshot
10.9.3. Operating Business Segments
10.9.4. Product Portfolio
10.9.5. Business Performance
10.9.6. Key Strategic Moves and Developments
10.10. Teva Pharmaceutical Industries Ltd.
10.10.1. Company Overview
10.10.2. Company Snapshot
10.10.3. Operating Business Segments
10.10.4. Product Portfolio
10.10.5. Business Performance

Companies Mentioned

  • Abbott Laboratories
  • Allergan Plc
  • F Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Merck & Co Inc
  • Mylan NV
  • Novartis International AG (Sandoz)
  • Pfizer Inc
  • Sanofi
  • Teva Pharmaceutical Industries Ltd

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...